BALL, Philadelphia chromosome
Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination with chemotherapy in adult patients who have recently been diagnosed with..
Asciminib, chronic myeloid leukemia, Novartis AG, Ph+ CML, Philadelphia chromosome, Scemblix
Asciminib is approved for Philadelphia chromosome-positive chronic myeloid leukemia
Nov 2021: Asciminib (Scemblix, Novartis AG) was given accelerated approval by the Food and Drug Administration for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who had pr..